Business Standard

Glenmark, Cyndea Pharma to develop complex drugs for US, Canada markets

Partnership to allow Glenmark to expand its dosage forms and launch new products

pharma, pharma industry
Premium

Govt proposes to bring fixed-dose combinations under price control

Aneesh Phadnis Mumbai:
Glenmark has tied up with Spanish firm Cyndea Pharma to develop complex drugs for US and Canada markets.
Following the tie up Glenmark will develop soft-gelatin capsule products under the technology license from the Spanish drug maker. The partnership allows Glenmark to expand its dosage forms and launch new products. Glenmark earns over 35 per cent revenue from US but the market is seeing increased competition and pricing pressure.
Developing an in-house technology for soft-gelatin capsules would have taken longer and the tie up will quicken product launches for Glenmark.
Glenmark's president (North America) Robert Matsuk said as many as 70 per cent of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in